GENETIC DISEASE: PATIENTS; MOLECULES AND PREVENTION H. Galjaard Erasmus University, Head Dept. Clinical Genetics, University Hospital, Rotterdam Congenital disorders become the major cause of infant mortality and morbidity in an increasing number of countries. The possibilities of primary prevention are very limited and the main emphasis has therefore been on newborn screening and early treatment, and on the early identification of couples at risk, genetic counseling and prenatal diagnosis followed by selective abortion. Enzyme replacement therapy has been attempted in patients with various types of lysosomal storage diseases and "gene therapy" is foreseen in patients with genetic disorders of the haemopoietic system. It seems, however, that in this area more basic research is needed about the exact nature of the molecular defect involved, the routing of gene products within the body, the efficiency of their uptake by various types of mutant cells and the corrective effect on cell metabolism of exogenous (enzyme) protein. Some of these aspects will be illustrated by experimental work on the genetic, molecular and cellular background of a number of lysosomal storage diseases. At present the most effective approach towards prevention of handicaps is the early diagnosis of index patients with a chromosomal aberration, a genetic disease or other types of congenital anomalies followed by genetic counseling of relatives at increased risk. Various follow-up studies indicate that a high proportion of couples who are informed about an increased risk of affected offspring are deterred from a (next) pregnancy. For those who still want to reproduce, there is the option of chorion analysis, amniotic fluid (cell) analysis or Ultrasonography in each pregnancy. The scope of prenatal diagnosis will be further widened by the possibilities of demonstrating gene mutations or polymorphisms closely linked to disease using recombinant DNA technology. Also for genetic diseases with a relatively high incidence, carrier screening programmes will enable couples to prevent the birth of a first affected baby in their family. In the future, the technology will also allow the prediction of diseases or of increased susceptibility to environmental factors. Such developments require timely attention to psychological, social and educational aspects. Such factors also playa major role in the participation of presently available technology as will be illustrated by Lysosomal enzymes are synthesized at the rough endoplasmic reticulum as glycosylatedprecursors of high molecular weight. In the endoplasmic reticulum and following in the Golgi complex they undergo a series of modifications that involve cleavage of the aminoterminal signal peptide, disulfide binding, oligoReplacement treatment by the use of pure enzymes in saccharide processing and subunit association.
various lysosomal storage diseases (LSD) has as yet Mannose 6-phosphate residues added in the Golgi not produced permanent clinical improvement. Brady complex serve as a signal for recognition by et al have attempted this in both Gaucher's disease mannose 6-phosphate specific receptors. The receptor- (1) and Niemann-Pick Disease (2) using enzyme made ligand complexes are routed to a prelysosomal acidic from human placenta. Neither has implantation of compartment, where the lysosomal enzymes and recepfibroblasts (3) or amnion-epithelial cells (4) given tors dissociate. The receptors return to the site, any beneficial effects. where they bind lysosomal enzymes (within or distal In this paper evidence will be produced to show that to the trans-Golgi). A second mannose 6-phosphate a successful bone marrow transplantation (BMT) can receptor dependent pathway ensures receptor-mediated produce an everlasting source of enzyme. When the endocytosis of (exogenous) lysosomal enzymes. The missing enzyme can be demonstrated in the white pathways for receptor-mediated transport of endocells, and that this treatment can be clinically efgenous and exogenous lysosomal enzymes are connected fective. and both involve clathrin-coated vesicles. The lysoso-In Wolman's Disease a satisfactory graft resulted in mal enzymes released from the receptors are transpor-an adequate ievel of acid esterase and acid lipase ted to lysosomes, where they undergo a limited both in the white cells and in liver biopsy along proteolysis, termed maturation. It has become apparent wi th mobilisation and disappearance of cholesterol that defective activity of a lysosomal enzyme in a from the liver (5). lysosomal storage disease can be caused by one of the In GM 1 gangliosidosis a stable white cell engraftfollowing reasons: 1. Defective synthesis of the ment ed to the disappearance of the hepatolysosomal enzyme polypeptide. 2. Defective transport splenomegaly but there was no improvement in the of the newly synthesized lysosomal enzyme to neurological regression, so that the patient died lysosomes. 3. Instability of the lysosomal enzyme fourteen months after the graft, thus not altering polypeptide within the lysosomes. 4. Deficiency in a the natural history of the disease (6) . cofactor required for activation of the lysosomal In Niemann~Pick Disease type B (non-neurological) a enzyme or for presenting the substrate. 5. Synthesis successful graft has led to some diminution in the of a catalytically inactive lysosomal enzyme polystored sphingomyelin within 80 days of BMT.Hopefully peptide. A single mutation may affect several of the adequate engraftment of normal marrow will conthese parameters, e.g. catalytic activity and stabili-tinue to produce a normal white cell level of the ty or transport properties and stability. missing enzyme, sphingomyelinase, which will lead The lysosomal storage disorders in which different to the disappearance of the hepatosplenomegaly in mutations have been identified by studying the biotime, as has occurred in all other cases of LSD so synthesis and processing of lysosomal enzymes comprise far transplanted. the following disorders: M. Tay-Sachs (1,2), Pompe
Five cases of Gaucher's Disease have been successfully (3, 4) , fucosidosis (5), metachromatic leukodystrophy engrafted with complete resolution of the hepato-(6), Gaucher (7), Fabry (8) and Maroteaux-Lamy (9).
splenomegaly, clearing of the lung infiltrate and The analysis of the molecular defects in lysosomal slow improvement in the radiological appearances of storage disorders using -the recently cloned cDNAs for the bones, clinically a very satisfactory result lysosomal enzymes will provide an increased under- 
